(MENAFN- GlobeNewsWire – Nasdaq) The study, which evaluated the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its number one endpoint. Prolia® and Xgeva® (denosumab) are indicated for the remedy. of bone diseases.
Alvotech (NASDAQ: ALVO), a global biotechnology company focused on the progression and production of biosimilars for patients around the world, today announced positive first-line effects from a pharmacokinetic (PK) study of AVT03, a biosimilar candidate from Prolia® and Xgeva®. Matrix any of which involves denosumab.
The pharmacokinetic study (AVT03-GL-P01), which evaluated the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints. Recently, a confirmatory study of the efficacy of AVT03 in patients is being conducted. as well as an ongoing pharmacokinetic examination comparing AVT03 with Xgeva® in healthy adult subjects.
“We are very pleased with the progress of our AVT03 program. This milestone, along with the recent positive effects of other clinical studies, clearly demonstrates our functions and the excellence of Alvotech’s biosimilar progression platform,” said Joseph McClellan, Chief Scientific Officer.
Prolia (denosumab) is indicated for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women at increased risk of fracture. Xgeva, which is also denosumab but in another presentation, is indicated for the prevention of diseases related to the skeleton. Occasions such as pathological fractures in adults with complex malignancies affecting the bones. It is also indicated for the treatment of giant mobile bone tumors. In the twelve months ending September 30, 2023, combined international net revenue was reported from sales of Prolia and Xgeva. amounted to more than $6 billion, based on quarterly sales reported through the manufacturer.
About AVT03 (denosumab) AVT03 is a human monoclonal antibody and a biosimilar candidate for Prolia® and Xgeva® (denosumab). Denosumab targets and binds with maximum affinity and specificity to the membrane protein of the RANK ligand, avoiding the RANK/RANK ligand interaction. resulting in relief in the number and function of osteoclasts, thereby reducing bone resorption and cancer-induced bone destruction [1]. AVT03 is an investigational product and has not obtained regulatory approval in any country. Biosimilarity has not been demonstrated through regulatory governance and is not claimed.
[1]
Prolia and Xgeva are registered by Amgen Inc.
About Alvotech Alvotech is a biotechnology company founded by Robert Wessman and focused solely on the progression and production of biosimilar medicines for patients worldwide. Alvotech seeks to become a global leader in biosimilars by offering high-quality, cost-effective products and services, made possible through fully incorporated technology and extensive in-house capabilities. Alvotech’s existing portfolio includes eight biosimilar applicants disclosed for the treatment of autoimmune diseases, eye disorders, osteoporosis, respiratory diseases and cancer. Alvotech has formed a network of strategic business partnerships to deliver global success and leverage local expertise in markets such as the United States, Europe, Japan, China and other Asian countries and major parts of South America, Africa and the Middle East. Alvotech’s commercial components are Teva Pharmaceuticals, a US subsidiary of Teva Pharmaceutical Industries Ltd. (USA), STADA Arzneimittel AG (EU), Fuji Pharma Co. , Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia). and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co. , Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co. , Ltd. (Thailand, Vietnam, Philippines and South Korea). Each business component covers a unique set of products and territories. Unless otherwise indicated, Alvotech disclaims all responsibility for the content of periodic documents, disclosures and other reports made through its components. For more data, visit. None of the data on Alvotech’s online page will be considered part of this press release.
Forward Looking Statements Certain statements in this communication may be considered“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, outcome of a reinspection of Alvotech’s manufacturing facility, the satisfactory responses to the FDA’s inspection findings and resolution of other deficiencies conveyed following the reinspection of Alvotech’s manufacturing site, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as“may”,“should”,“expect”,“intend”,“will”,“estimate”,“anticipate”,“believe”,“predict”,“potential”,“aim” or“continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against Alvotech or others following the business combination between Alvotech Holdings S.A., Oaktree Acquisition Corp. II and Alvotech; (2) the ability to raise substantial additional funding, which may not be available on acceptable terms or at all; (3) the ability to maintain stock exchange listing standards; (4) changes in applicable laws or regulations; (5) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (6) Alvotech’s estimates of expenses and profitability; (7) Alvotech’s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (8) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (9) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (10) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (11) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (12) the ability of Alvotech’s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (13) Alvotech’s ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (14) the success of Alvotech’s current and future collaborations, joint ventures, partnerships or licensing arrangements; (15) Alvotech’s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (16) Alvotech’s ability to manufacture sufficient commercial supply of its approved products; (17) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (18) the potential impact of the ongoing COVID-19 pandemic on the FDA’s review timelines, including its ability to complete timely inspection of manufacturing sites; (19) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Company’s business, financial position, strategy and anticipated milestones; and (20) other risks and uncertainties set forth in the sections entitled“Risk Factors” and“Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.
CONTACTS Investor Relations & Media Contact: Benedikt Stefansson, Senior Director. . .
MENAFN29012024004107003653ID1107779906
Tags
Comments
Category
Date